Indivior Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
24.6%projected annual EPS growth
Analyst Coverage
4analysts covering
FY Revenue (est.)
$1.3Bnext fiscal year
FY EPS (est.)
$4.41next fiscal year
Monitoring Framework
Key Performance Indicators
SUBLOCADE Net Revenue Quarterly232MTarget: $905 million to $945 million
SUBLOCADE New Patient Starts Quarterly31.8KTarget: Accelerate dispense unit growth in the mid-teens percentage range for FY 2026
Adjusted EBITDA Quarterly164MTarget: $620 million to $660 million
Watch Items
- SUBLOCADE Market Concentration and Growth DurabilityTrigger: Slowing of dispense unit growth below mid-teens percentage range
- Gross-to-Net (GTN) Adjustments and Pricing Pressures
- Pipeline Setbacks and R&D Rationalization
Research as of 19 Jun 2026